Nuwellis, Inc. (NUWE)
After hours:
| Previous Close | 0.2158 |
| Open | 0.2160 |
| Bid | 0.2235 x 100 |
| Ask | 0.2290 x 100 |
| Day's Range | 0.2139 - 0.2350 |
| 52 Week Range | 0.1300 - 2.8200 |
| Volume | |
| Avg. Volume | 6,482,480 |
| Market Cap | 3.932M |
| Beta (5Y Monthly) | 0.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.3600 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.00 |
GlobeNewswireNuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™
MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the recent grant of a new patent from the United States Patent and Trademark Office (USPTO) related to its groundbreaking pediatric continuous renal replacement therapy (CRRT), Vivian™. This patent covers critical advancements that will significantly improve the performance and user experience of Vivian. This i
- GlobeNewswire
Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase
Pilot Collaboration for Aquadex® Ultrafiltration Therapy for Adult Patients with Congestive Heart Failure is extended to August 31, 2024MINNEAPOLIS, June 06, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, today announced the extension of its pilot phase under its previously announced supply and collaboration agreement with DaVita Inc. (NYSE: DVA) until August 31, 2024. This p
- GlobeNewswire
Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida
MINNEAPOLIS, May 14, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the launch of a new pediatric ultrafiltration program utilizing Nuwellis' Aquadex SmartFlow System® at one of the largest health integrated delivery networks (IDN) in Florida. This program marks an expansion by this network to offer ultrafiltration to its pediatric patients, in addition to its current heart fail
